Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
95 hedge funds and large institutions have $195M invested in Accelerate Diagnostics in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 31 reducing their positions, and 16 closing their positions.
4% less funds holding
Funds holding: 99 → 95 (-4)
5% less capital invested
Capital invested by funds: $205M → $195M (-$10.4M)
19% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 31
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
35% less call options, than puts
Call options by funds: $1.13M | Put options by funds: $1.73M
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$1.36M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$692K |
| 3 |
CI
Chartist Inc
Seal Beach,
California
|
+$515K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$422K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$412K |
Top Sellers
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$3.22M |
| 2 |
Rafferty Asset Management
New York
|
-$1.1M |
| 3 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
-$698K |
| 4 |
CC
Chicago Capital
Chicago,
Illinois
|
-$696K |
| 5 |
Renaissance Technologies
New York
|
-$662K |
AXDX Hedge Fund Activity: Q2 2021 in Review
95 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q2 2021, worth a combined $195M — down 5.1% from $205M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AXDX and 12 opened new positions — a net loss of 4 holders — while 31 trimmed existing stakes and 25 added.
The largest buyer was State Street, adding an estimated $1.36M. The largest seller was Credit Suisse, cutting an estimated $3.22M.
- 95 institutional investors held Accelerate Diagnostics (AXDX) as of Q2 2021, down from 99 in Q1 2021.
- Funds reported $195M of Accelerate Diagnostics stock for Q2 2021, down 5.1% quarter-over-quarter.
- 12 funds opened new Accelerate Diagnostics positions in Q2 2021 and 16 closed out, a net change of -4 holders.
- The largest Accelerate Diagnostics buyer in Q2 2021 was State Street, an estimated $1.36M added.
- The largest Accelerate Diagnostics seller in Q2 2021 was Credit Suisse, an estimated $3.22M sold.
Based on aggregated 13F filings for Q2 2021.